Evidence map›Paper›PMID 38970095›Full record

ArticleMolecular cancer2024

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients.

Lenka Hovorkova, Lucie Winkowska, Justina Skorepova, Manuela Krumbholz, Adela Benesova, Vaclava Polivkova, Julia Alten, Michela Bardini, Claus Meyer, Rathana Kim and 15 more

Abstract readLetter
In one paragraph

Article in Molecular cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Lenka HovorkovaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Lucie WinkowskaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Justina SkorepovaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Manuela KrumbholzPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany.
Adela BenesovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Vaclava PolivkovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Julia AltenDepartment of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.
Michela BardiniTettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Claus MeyerInstitute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe-University, Frankfurt, Germany.
Rathana KimHematology laboratory, AP-HP, Saint-Louis hospital, Université Paris-Cité, Paris, France.
Toby N TrahairChildren's Cancer Institute, Randwick, Australia.
Emmanuelle ClappierHematology laboratory, AP-HP, Saint-Louis hospital, Université Paris-Cité, Paris, France.
Sabina ChiarettiDivision of Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Michelle HendersonChildren's Cancer Institute, Randwick, Australia.
Rosemary SuttonChildren's Cancer Institute, Randwick, Australia.
Lucie SramkovaDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic.
Jan StaryDepartment of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University/University Hospital Motol, Prague, Czech Republic.
Katerina Machova PolakovaInstitute of Hematology and Blood Transfusion, Prague, Czech Republic.
Rolf MarschalekInstitute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe-University, Frankfurt, Germany.
Markus MetzlerPediatric Oncology and Hematology, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany.
Giovanni CazzanigaTettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Gunnar CarioDepartment of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.
Jan TrkaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Marketa ZaliovaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic.
Jan ZunaCLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. JAN.ZUNA@LFMOTOL.CUNI.CZ.

Funding

Cancer Australia PdCCRS1128727Charles University GAUK 327322Czech Health Research Council NU21-03-00128MH CZ - DRO IHBT, 00023736Ministry of Health, Czech Republic 00064203National Institute for Cancer Research Program EXCELES, ID Project No. LX22NPO5102
6 · The paper itself

Abstract

backgroundThe BCR::ABL1 is a hallmark of chronic myeloid leukemia (CML) and is also found in acute lymphoblastic leukemia (ALL). Most genomic breaks on the BCR side occur in two regions - Major and minor - leading to p210 and p190 fusion proteins, respectively.

methodsBy multiplex long-distance PCR or next-generation sequencing technology we characterized the BCR::ABL1 genomic fusion in 971 patients (adults and children, with CML and ALL: pediatric ALL: n = 353; pediatric CML: n = 197; adult ALL: n = 166; adult CML: n = 255 patients) and designed "Break-App" web tool to allow visualization and various analyses of the breakpoints. Pearson's Chi-Squared test, Kolmogorov-Smirnov test and logistic regression were used for statistical analyses.

resultsDetailed analysis showed a non-random distribution of breaks in both BCR regions, whereas ABL1 breaks were distributed more evenly. However, we found a significant difference in the distribution of breaks between CML and ALL. We found no association of breakpoints with any type of interspersed repeats or DNA motifs. With a few exceptions, the primary structure of the fusions suggests non-homologous end joining being responsible for the BCR and ABL1 gene fusions. Analysis of reciprocal ABL1::BCR fusions in 453 patients showed mostly balanced translocations without major deletions or duplications.

conclusionsTaken together, our data suggest that physical colocalization and chromatin accessibility, which change with the developmental stage of the cell (hence the difference between ALL and CML), are more critical factors influencing breakpoint localization than presence of specific DNA motifs.

Indexed as

Chromosome BreakpointsFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor Cell Lymphoblastic Leukemia-LymphomaAdultChildFemaleHigh-Throughput Nucleotide SequencingHumansMaleFusion Proteins, bcr-ablABL1Acute lymphoblastic leukemiaBCRChronic myeloid leukemiaGenomic breakpoints

Identifiers

PMID38970095
PMCPMC11229488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.